Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review

Gebo, M.P.H. Kelly A.; Chander, Geetanjali; Jenckes, Mollie W.; Ghanem, Khalil G.; Herlong, H. Franklin; Torbenson, Michael; El-Kamary, Samer S.; Bass, Eric B.

doi:10.1053/jhep.2002.36817

Cited by 84 publications

(63 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AFP is widely used as a serological marker for HCC and germ-cell tumors [17][18][19][20][21][22] . AFP value 10 ng/mL is generally regarded as the upper limit of normal range, with presence of cancer suspected when AFP value increases above this value.…”

Section: Discussionmentioning

confidence: 99%

Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

Takeuchi

Ikeda

Osawa

et al. 2015

WJH

View full text Add to dashboard Cite

AIM:To investigate factors that accurately predict hepatocellular carcinoma (HCC) development after antiviral therapy in chronic hepatitis C (CHC) patients. METHODS:CHC patients who received pegylated interferon and ribavirin were enrolled in this cohort study that investigated the ability of alpha-fetoprotein (AFP) to predict HCC development after interferon (IFN) therapy. RESULTS:Of 1255 patients enrolled, 665 developed sustained virological response (SVR) during mean follow-up period of 5.4 years. HCC was occurred in 89 patients, and 20 SVR patients were included. Proportional hazard models showed that HCC occurred in SVR patients showing AFP ≥ 5 ng/mL before therapy and in non-SVR patients showing AFP ≥ 5 ng/mL before and 1 year after therapy besides older age, and low platelet counts. SVR patients showing AFP ≥ 5 ng/mL before therapy and no decrease in AFP to < 5 ng/mL 1 year after therapy had significantly higher HCC incidence than non-SVR patients showing AFP ≥ 5 ng/ mL before therapy and decreased AFP (P = 0.043). AFP ≥ 5 ng/mL before therapy was significantly associated with low platelet counts and high values of alanine aminotransferase (ALT) in stepwise logistic regression analysis. After age, gender, platelet count, and ALT was matched by propensity score, significantly lower HCC incidence was shown in SVR patients showing AFP < 5 ng/mL before therapy than in those showing AFP ≥ 5 ng/mL. CONCLUSION:The criteria of AFP < 5 ng/mL before and 1 year after IFN therapy is a benefical predictor for HCC development in CHC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

Takeuchi

Ikeda

Osawa

et al. 2015

WJH

View full text Add to dashboard Cite

show abstract

“…Several studies indicate that surveillance programs could lead to more frequent detection of HCC at early stages, when curative treatment is still possible [60,61,66,67] . In the previously mentioned large randomized controlled trial by Yang et al [61] , more resectable HCC cases were detected in the surveillance group than in the disease control group during five years follow-up (OR = 7.14; 95%CI: 3.…”

Section: Surveillance Efficiencymentioning

confidence: 99%

“…In the systematic review by Gebo et al [66] covering publications in the period: 1996-2002, one prospective cohort study was identified that investigated HCC surveillance in HCV patients. This study by Solmi et al [67] , compared 360 patients in the surveillance group (combined US and AFP measurements at 6-mo intervals) with a disease control group of 2170 patients who received usual care in other hepatology clinics.…”

Section: Surveillance Efficiencymentioning

confidence: 99%

Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies

Meer¹

2013

WJG

View full text Add to dashboard Cite

Primary liver cancer is the sixth most common cancer in the world and the third cause of cancer-related death. Hepatocellular carcinoma (HCC) represents more than 90% of primary liver cancers and generally occurs in patients with underlying chronic liver disease such as viral hepatitis, hemochromatosis, primary biliary cirrhosis and non-alcoholic steatohepatitis. Especially cirrhotic patients are at risk of HCC and regular surveillance could enable early detection and therapy, with potentially improved outcome. We here summarize existing evidence for surveillance including ultrasound, other radiological modalities and various serum biomarkers, and current international guideline recommendations for surveillance. Ultrasound and α-fetoprotein (alone or in combination) are most frequently used for surveillance, but their sensitivities and specificities are still far from perfect, and evidence for surveillance remains weak and controversial. Various other potential surveillance tools have been tested, including serum markers as des-carboxyprothrombin, lectin-bound α-fetoprotein, and (most recently) circulating TIE2-expressing monocytes, and radiological investigations such as computed tomography-scan or magnetic resonance imaging-scan. Although early results appear promising, these tools have generally been tested in diagnostic rather than surveillance setting, and in most cases, no detailed information is available on their cost-effectiveness. For the near future, it remains important to define those patients with highest risk of HCC and most benefit from surveillance, and to restrict surveillance to these categories.

show abstract

“…Twenty-four studies, which included patients with chronic hepatitis B or C or both, addressed the sensitivities and specificities of screening tests [106]. …”

Section: Epidemiology Of Hepatocellular Carcinomamentioning

confidence: 99%

Untitled

2005

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The incidence of HCC varies considerably with the geographic area because of differences in the major causative factors. Chronic hepatitis B and C, mostly in the cirrhotic stage, are responsible for the great majority of cases of HCC worldwide. The geographic areas at the highest risk are South-East Asia and sub-Saharan Africa, here hepatitis B is highly endemic and is the main cause of HCC. In areas with an intermediate rate of HCC such as Southern Europe and Japan, hepatitis C is the predominant cause, whereas in low rate areas such as Northern Europe and the USA, HCC is often related to other factors as alcoholic liver disease. There is a rising incidence in HCC in developed countries during the last two decades, due to the increasing rate of hepatitis C infection and improvement of the clinical management of cirrhosis.

show abstract

Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review

Cited by 84 publications

References 49 publications

Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies

Untitled

Contact Info

Product

Resources

About